(3)无进展生存(progress free survival,PFS) 无进展生存指从随机分组开始到肿瘤进展或死亡时间,该指标的优点是比OS观察所需时间短且样本量少,既反映肿瘤的生长,又可以在证实生存受益以前进行评价,不会使现有治疗受到潜在的其他治疗的混淆,目前认为可以接受作为可能预测OS临床获益的替代指标。其缺点是,目前对无进展生存...
声明: 本网站大部分资源来源于用户创建编辑，上传，机构合作，自有兼职答题团队，如有侵犯了你的权益，请发送邮箱到feedback@deepthink.net.cn 本网站将在三个工作日内移除相关内容,刷刷题对内容所造成的任何后果不承担法律上的任何义务或责任
_, err = os.Stat(filepath.Join(directory, repoName)) require.NoError(t, err) _, err = os.Stat(filepath.Join(directory, repoName,"scratch")) require.NoError(t, err) commit, err := pfsutil.StartCommit(apiClient, repoName,"scratch") require.NoError(t, err) require.NotNil(t, ...
'pps I buy1om panuuo am sy.aqo1s,ays adoy I.. 'pps ay ..'11aM . 'aym o uayssom3H .'p106 ays10y1dn moys 1,uppI asnoqsomypu,, 'paysay .iaay1somays oS, oof sy ano puny sy passod ay1n"i山quoN o 4 I3y1 q II qu3 3 3q1,p1no10p10 1 5 1 y1 y1'1 p11 I....
_, err = os.Stat(filepath.Join(directory, repoName,"scratch")) require.NoError(t, err) commit, err := pfsutil.StartCommit(apiClient, repoName,"scratch") require.NoError(t, err) require.NotNil(t, commit) newCommitID := commit.Id ...
ppsClient := getPpsClient(t) job, err := ppsutil.CreateJob( ppsClient,"", []string{"cp", path.Join("/pfs", dataRepo,"file"),"/pfs/out/file"},"",1, []*pfs.Commit{commit},"", ) require.NoError(t, err) inspectJobRequest := &pps.InspectJobRequest{ ...
pfsdAddr := os.Getenv("PFSD_PORT_650_TCP_ADDR")ifpfsdAddr ==""{ tb.Error("PFSD_PORT_650_TCP_ADDR not set") } clientConn, err := grpc.Dial(fmt.Sprintf("%s:650", pfsdAddr), grpc.WithInsecure()) require.NoError(tb, err)returnpfs.NewAPIClient(clientConn) ...
require.Equal(t, pps.JobState_JOB_STATE_SUCCESS.String(), jobInfo.State.String()) commitInfo, err := pfsutil.InspectCommit(pachClient, jobInfo.OutputCommit.Repo.Name, jobInfo.OutputCommit.Id) require.NoError(t, err) require.Equal(t, pfs.CommitType_COMMIT_TYPE_READ, commitInfo.CommitType)...
This standard Stupp regimen extends the overall survival (OS) from 12.1 months with postoperative radiotherapy alone to 14.6 months. However, the optimal duration of maintenance therapy remains a matter of debate. In clinical practice, investigators often prolong treatment in nonprogressive patients [17...